MedicarePartD.guide

A non-government resource built from CMS public data

GLP-1 drugs on every 2026 Nevada Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Nevada cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days
GLP-1 drugs by 2026 Nevada Part D plan
DrugHumana Basic Rx Plan$0.00/moS5884-112Wellcare Classic$2.70/moS4802-093Wellcare Value Script$2.70/moS4802-161Humana Value Rx Plan$43.70/moS5884-208HealthSpring Extra Rx$52.60/moS5617-379AARP Medicare Rx Saver from UHC$76.70/moS5921-373HealthSpring Assurance Rx$95.60/moS5617-143SilverScript Choice$97.40/moS5601-058AARP Medicare Rx Preferred from UHC$139.10/moS5921-410Humana Premier Rx Plan$148.70/moS5884-175
Ozempicsemaglutide injectionTier 3PA25%QL 3/28dTier 3PA25%QL 3/28dTier 6PA$11.00QL 3/28dTier 3PA18%QL 3/28dTier 3PA17%QL 3/28dTier 3PA19%QL 3/28dTier 3PA20%QL 3/28dTier 5PA25%QL 3/28dTier 3PA18%QL 3/28dTier 3PA$45.00QL 3/28d
Mounjarotirzepatide injectionTier 3PA25%QL 2/28dTier 3PA25%QL 2/28dTier 6PA$11.00QL 2/28dTier 3PA18%QL 2/28dTier 3PA17%QL 2/28dTier 3PA19%QL 2/28dTier 3PA20%QL 2/28dTier 5PA25%QL 2/28dTier 3PA18%QL 2/28dTier 3PA$45.00QL 2/28d
Trulicitydulaglutide injectionNot coveredTier 3PA25%QL 2/28dTier 6PA$11.00QL 2/28dNot coveredTier 3PA17%QL 2/28dTier 3PA19%QL 2/28dTier 3PA20%QL 2/28dTier 5PA25%QL 2/28dTier 3PA18%QL 2/28dNot covered
Ozempic tabletsoral semaglutide, formerly RybelsusNot coveredTier 3PA25%QL 30/30dTier 6PA$11.00QL 30/30dNot coveredTier 3PA17%QL 30/30dTier 3PA19%QL 30/30dTier 3PA20%QL 30/30dTier 5PA25%QL 30/30dTier 3PA18%QL 30/30dNot covered
Wegovysemaglutide, weightNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Zepboundtirzepatide, weightNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
VictozaliraglutideNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
liraglutidegeneric VictozaNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
Saxendaliraglutide, weightNo 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are).
ByettaexenatideNo 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are).
Bydureon BCiseexenatide extended-releaseNo 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are).
orforglipronoral GLP-1, approved 2026No 2026 Part D formulary lists this drug in the CMS files: it is too new, no longer sold, or excluded from Part D (as weight-loss-only drugs are).

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.